5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
Deep-dive into published cost-effectiveness analyses of semaglutide 2.4 mg from STEP-1: cost per QALY, payer coverage gaps, list vs net pricing, and value calculations for patients considering treatment.
Deep-dive into STEP-1 follow-up and extension data for semaglutide 2.4 mg, covering weight regain after discontinuation, long-term safety signals, and durability of cardiometabolic benefits.
A deep dive into the STEP-1 trial's primary and secondary endpoints for semaglutide 2.4 mg, including effect sizes, confidence intervals, response distribution, and week-by-week weight-loss trajectory.
Deep dive into STEP-1 pre-specified and post-hoc subgroup analyses by age, sex, BMI, race, and baseline biomarkers, revealing which patients lost the most weight on semaglutide 2.4 mg.
In STEP-1 (NEJM 2021), adults taking semaglutide 2.4 mg lost a mean 14.9% of body weight over 68 weeks vs 2.4% on placebo; about a third lost 20% or more.